These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 1330859)

  • 1. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Augmentation of LAK cell-accumulation in tumor tissue and its therapeutic effect after chemotherapy].
    Wakizaka Y; Uchino J
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1441-4. PubMed ID: 1530290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms of enhanced accumulation of transferred LAK cells into tumor sites after chemotherapy].
    Kuramitsu Y
    Hokkaido Igaku Zasshi; 1995 May; 70(3):507-17. PubMed ID: 7590601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmented accumulation of transferred lymphokine-activated killer (LAK) cells at murine tumor sites through production of LAK-attractant facilitated by chemotherapy.
    Hosokawa M; Wakizaka Y; Kuramitsu Y; Micallef M; Togashi Y; Kobayashi H
    Tohoku J Exp Med; 1992 Oct; 168(2):413-6. PubMed ID: 1306328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation, or splenectomy.
    Kawata A; Hosokawa M; Sawamura Y; Ito K; Une Y; Shibata T; Uchino J; Kobayashi H
    Mol Biother; 1990 Dec; 2(4):221-7. PubMed ID: 2288722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN; Khoo NK; Lala PK
    Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
    Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
    Ann Ist Super Sanita; 1990; 26(3-4):423-32. PubMed ID: 2091504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
    Basse PH
    APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adopted immunochemotherapy using IL-2 and spleen LAK cell--randomized study].
    Une Y; Kawata A; Uchino J
    Nihon Geka Gakkai Zasshi; 1991 Sep; 92(9):1330-3. PubMed ID: 1658591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.